- Atlas Arteria reports 1Q Weighted Average Toll Revenue Year/Year increase of 2.9%.
- The company experienced a slight decrease in Weighted Average Traffic Year/Year by 0.7%.
- The fluctuation in year-on-year measurements is primarily due to weaker traffic performance at APRR following farmers’ strikes in France. These protests led to both road closures and motorway blockades for two weeks.
- Despite lower traffic numbers than the previous year, the Chicago Skyway toll revenue saw an increase due to higher toll rates being implemented.
- Based on the performance data, the consensus analyst rating for Atlas Arteria is mixed: 1 buy, 8 holds, and 2 sells.
A look at Atlas Arteria Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Atlas Arteria Limited, an infrastructure developer and operator, has garnered positive feedback from the Smartkarma Smart Scores system, with high ratings in dividend, value, and growth. The company’s robust dividend score of 5 reflects its strong performance in rewarding its shareholders. With a value score of 4, Atlas Arteria showcases promising investment potential based on its current market position. Additionally, a growth score of 4 indicates a positive outlook for the company’s expansion and development projects.
Despite lower scores in resilience and momentum, with ratings of 3 each, Atlas Arteria remains well-positioned for long-term success in the infrastructure sector. The company’s global outreach and focus on constructing highways, roads, bridges, and tunnels contribute to its overall stability. Investors may find Atlas Arteria an attractive prospect for consistent dividends, growth opportunities, and solid value in the infrastructure market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
